# US 10,118,034 B2 · Methods for producing cardiomyocyte cells > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,118,034 B2 - Document ID: US10118034B2 - Status: Granted - Kind: B2 - Application number: 15/239,565 - Filed: 2016-08-17 - Published: 2017-02-23 - Granted: 2018-11-06 - Earliest claimed: 2015-08-18 - Assignees: Boston Scientific Scimed, Inc. - Applicants: Boston Scientific Scimed Inc. - Inventors: Thomas J. Herbst; Craig Stolen - Web page: https://patentgrep.com/patent/US10118034B2 ## CPC - A61N 1/326: {for promoting growth of cells, e.g. bone cells} - A61N 1/056: {Transvascular endocardial electrode systems} - A61N 1/0573: {chacterised by means penetrating the heart tissue, e.g. helix needle or hook} - A61N 1/205: {for promoting a biological process} - A61N 1/3628: {using sub-threshold or non-excitatory signals} - A61N 1/3756: {Casings with electrodes thereon, e.g. leadless stimulators} - C12N 5/0657: {Cardiomyocytes; Heart cells} - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells. ## Claims ### Claim 1 A method for producing cardiomyocyte cells comprising: implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium, and a second portion of the substrate is not in contact with the endocardium; maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, wherein the trabecular fibers include cardiomyocyte cells; cutting away the trabecular fibers from the endocardium; cutting away the trabecular fibers from the substrate; and removing the trabecular fibers from the heart. ### Claim 2 (depends on 1) The method of claim 1, wherein the substrate is implanted percutaneously. ### Claim 3 (depends on 1) The method of claim 1, wherein the substrate is implanted within a right ventricle of the heart. ### Claim 4 (depends on 1) The method of claim 1, wherein the substrate includes a biocompatible polymer. ### Claim 5 (depends on 4) The method of claim 4, wherein the biocompatible polymer is selected from the group consisting of a polyurethane polymer, a polyether ether ketone polymer, and a silicone polymer. ### Claim 6 (depends on 1) The method of claim 1, wherein the trabecular fibers are cut from the endocardium at a location where the trabecular fibers extend from the endocardium. ### Claim 7 (depends on 1) The method of claim 1, wherein the trabecular fibers are cut from the substrate at a location where the trabecular fibers extend from the substrate. ### Claim 8 A method for producing cardiomyocyte cells comprising: implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium, and a second portion of the substrate is not in contact with the endocardium; maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient for trabecular fibers to form, the trabecular fibers extending between the endocardium and the second portion of the substrate, wherein the trabecular fibers include cardiomyocyte cells; cutting away the trabecular fibers from the endocardium; separating the first portion of the substrate from the endocardium; and removing the substrate and the attached trabecular fibers from the heart. ### Claim 9 (depends on 8) The method of claim 8, wherein the substrate is implanted within a right ventricle of the heart. ### Claim 10 (depends on 8) The method of claim 8, wherein the substrate includes a biocompatible polymer. ### Claim 11 (depends on 10) The method of claim 10, wherein the biocompatible polymer is selected from the group consisting of a polyurethane polymer, a polyether ether ketone polymer, and a silicone polymer. ### Claim 12 (depends on 8) The method of claim 8, wherein the trabecular fibers are cut from the endocardium at a location where the trabecular fibers extend from the endocardium. ### Claim 13 A method for producing cardiomyocyte cells comprising: positioning a substrate including an electrode within a heart such that the substrate is in physical contact with an endocardium, and the electrode is not in physical contact with the endocardium; maintaining the substrate within the heart for a time at least sufficient to form trabecular fibers extending between the endocardium and the electrode, wherein the trabecular fibers contain cardiomyocyte cells; cutting away the trabecular fibers from the endocardium; cutting away the trabecular fibers from the electrode; and removing the trabecular fibers from the heart. ### Claim 14 (depends on 13) The method of claim 13, wherein maintaining includes: anchoring the substrate to the endocardium with a fixation device; and producing an electrical potential between the electrode and the endocardium. ### Claim 15 (depends on 14) The method of claim 14, wherein the electrical potential is produced as a series of electrical pulses. ### Claim 16 (depends on 14) The method of claim 14, wherein the electrical potential is produced continuously. ### Claim 17 (depends on 13) The method of claim 13, wherein the substrate includes a biocompatible polymer and the electrode includes a biocompatible electrical conductor. ### Claim 18 (depends on 13) The method of claim 13, wherein the trabecular fibers are cut from the endocardium at a location where the trabecular fibers extend from the endocardium. ### Claim 19 (depends on 13) The method of claim 13, wherein the trabecular fibers are cut from the substrate at a location where the trabecular fibers extend from the electrode. ### Claim 20 (depends on 13) The method of claim 13, further including removing the substrate from the heart after removing the trabecular fibers containing the cardiomyocyte cells from the heart.